Length: 7 min read
Published: 27 April 2026
Medically Reviewed: By Dr Aqua Asif

Key Takeaways

  • UK Incidence – over 64,000 new diagnoses per year, a 24% rise on 2021 figures and now the UK’s most common cancer.
  • Lifetime risk – about 1 in 8 men overall, rising to around 1 in 4 for Black men and 1 in 13 for Asian men.
  • Age Matters – Risk increases strongly after age 50 and peaks between ages 75 – 79.
  • Early Stage Survival – around 85% at 5 years and 80% at 10 years when caught early.
  • Treatment Options – localised cancers may be eligible for focal therapy (HIFU, NICE IPG424/HTG667) and Nanoknife IRE, NICE IPG768/HTG688) to preserve urinary and sexual function.

Prostate cancer is now the most commonly diagnosed cancer in the UK, with over 64,000 new cases recorded annually and a lifetime risk of roughly 1 in 8 men rising to 1 in 4 men for Black men. Most diagnoses happen after age 50, and early-stage disease is highly treatable: around 85% of UK men survive at least 5 years after diagnosis. In our clinic’s experience. Early stage cancers are suitable for tissue preserving focal therapy therapy.

Prostate cancer incidence in the UK

Prostate cancer accounts for the highest number of new cancer diagnoses nationally. National registry data confirms a sustained rise in incidence. Increased awareness and improved diagnostics have fundamentally changed how frequently the disease is identified.

How many are diagnosed each year?

Recent NHS figures indicate a substantial increase in diagnoses, rising from just under 52,000 cases in 2021 to over 64,000 in 2022. This represents a 24 percent increase, meaning prostate cancer is now more commonly diagnosed than breast cancer in the UK.

Key figures include:

  • Over 64,000 new UK cases recorded annually in recent data.
  • Approximately 14 percent of all new cancer cases.
  • More than 540,000 men are currently living with or after a diagnosis.

Screening and testing context

There is no national screening programme for prostate cancer in the UK. Instead, men can request a PSA test after discussing risks and benefits with their GP.

Greater public awareness, often supported by high-profile campaigns, has encouraged more men to request testing. Earlier investigation can increase diagnosis rates and allows cancers to be identified at a stage where more treatment options may be available.

Lifetime risk and prevalence trends

When evaluating how common prostate cancer is, lifetime risk provides essential perspective. In the UK, around 1 in 8 men will be diagnosed during their lifetime.

Lifetime risk statistics

The average lifetime risk stands at approximately 12.8 percent. For some groups, this risk is significantly higher, highlighting the importance of personalised risk assessment.

Current estimates show:

  • 1 in 8 men overall will develop prostate cancer.
  • Around 1 in 4 black men will be diagnosed.
  • 1 in 13 Asian men will be diagnosed.

Growing prevalence

Prevalence refers to the number of men currently living with or beyond prostate cancer. Survival rates have improved over the last two decades.

Improved therapies and monitoring strategies support this trend. Early-stage cases form a large proportion of new diagnoses, creating opportunities for less invasive management that aims to preserve quality of life.

Age, demographics and risk factors

Prostate cancer risk varies between individuals. Certain demographic and biological factors increase the likelihood of diagnosis.

Age

Risk rises sharply with increasing age. Most cases occur in men over the age of 50, with incidence rates peaking in males aged 75 to 79.

Some patients ask how common prostate cancer is in young men. It remains uncommon in men under 50, though incidence does increase progressively with advancing age.

Ethnicity

Ethnicity significantly affects risk. Black men face approximately double the lifetime risk compared to White men, and they are often diagnosed at a younger age. Earlier discussions about testing are often recommended for these higher-risk groups, usually from age 45.

Family history

A strong family history increases risk. Men with a father or brother diagnosed with prostate cancer are more likely to develop the disease themselves. Genetic factors, such as a family history of breast cancer linked to inherited mutations, may also contribute.

Lifestyle and life expectancy

Rising life expectancy in the UK increases overall case numbers. Because prostate cancer is strongly age-related, an ageing population inevitably leads to more diagnoses. Research into the influence of lifestyle factors is ongoing.

Global vs UK comparison

Prostate cancer is common worldwide, but reported rates vary significantly. Differences in healthcare systems and testing access influence these statistics.

High-income countries

Northern Europe has the highest rates followed by the USA and the UK which are similar. Southern Europe is significantly lower. The widespread availability of PSA testing and advanced imaging can increase diagnosis rates. Early-stage detection is generally more common in these regions.

Lower-resource settings

Lower-income countries often report fewer diagnosed cases. Limited screening and diagnostic capacity can reduce detection, and mortality can be higher due to later-stage presentation. Timely access to imaging and biopsy is associated with improved survival outcomes.

Why are numbers rising?

The upward trend in prostate cancer diagnoses reflects several combined factors. This increase does not automatically indicate worsening disease severity across the population.

Ageing population

The UK population continues to age. As prostate cancer risk increases after 50, a larger older demographic results in higher overall case numbers.

Better detection and imaging

MRI Imaging allows clinicians to visualise suspicious areas with high accuracy. Targeted biopsy techniques further refine diagnosis, reducing unnecessary procedures and increasing the identification of clinically significant disease.

Recent diagnostic surges

Following periods of fluctuation, awareness campaigns and media coverage involving high-profile public figures have renewed public engagement. More men now proactively request testing. Additionally, data indicates a geographic variation in diagnosis, with men in some deprived areas facing a higher likelihood of late-stage diagnosis compared to those in more affluent areas.

Get Expert Advice & The Latest Research

Subscribe to our newsletter to receive the latest updates, expert insights, and breakthrough research on prostate cancer-delivered straight to your inbox.

    Survival rates and early detection impact

    Survival rates for prostate cancer are generally high when the disease is identified early. In the UK, around 85 percent of men survive at least 5 years, and approximately 80 percent survive for 10 years or more. Stage at detection strongly influences prognosis.

    Importance of early symptoms awareness

    Early symptoms are often mild or entirely absent. Urinary changes can occur but are frequently linked to benign conditions. Men should not wait for warning signs. Regular discussion with a GP is advised for those at increased risk.

    Impact on long-term outcomes

    Localised prostate cancer is associated with excellent survival outcomes. Early-stage management often results in fewer side effects, whereas advanced disease requires more complex systemic treatment. Prompt assessment can allow treatment decisions to focus on preserving function.

    Focal therapy for common early cases

    Many newly diagnosed prostate cancers are confined to the gland. This may make them suitable for targeted treatment approaches. The Focal Therapy Clinic specialises in the minimally invasive management of localised disease.

    What makes focal therapy different?

    Focal therapy aims to treat only the cancerous portion of the prostate. Healthy tissue is preserved wherever possible. This approach aims to preserve urinary continence and erectile function, reducing the likelihood of treatment-related complications.

    The clinic offers HIFU and Nanoknife procedures. These technologies use advanced imaging guidance to target tumours precisely.

    Clinical expertise and outcomes?

    The clinic’s clinicians have extensive experience, having completed over 2,100 focal therapy treatments. Around 90% show no clinically significant disease at one year from a recent audit.

    Reported complication rates remain low in appropriately selected patients:

    • Over 95 percent of men maintain full bladder control post-treatment at one year
    • Over 90 percent of men maintain erectile function at one year

    A comprehensive multidisciplinary team reviews every case. This balanced expertise provides patients with a thorough assessment of all treatment options.

    Access and patient-centred care

    Private pathways may help reduce waiting times. Patients can access some of the nearest clinics offering advanced MRI-ultrasound fusion technology. Treatment planning focuses on cancer control while aiming to maintain quality of life.

    How can I assess my risk?

    Understanding personal risk factors empowers proactive decision-making. Men over 50, Black men over 45, and those with a family history should consider early discussion with their GP.

    PSA testing and imaging

    A PSA test measures prostate-specific antigen levels in the blood. Elevated levels may require further evaluation. MRI imaging is often used before a biopsy to improve diagnostic precision and reduce unnecessary invasive procedures.

    Preparing for specialist consultation

    Men concerned about risk or symptoms may seek specialist advice. Bringing previous test results helps streamline the assessment. Patients can book a consultation to review imaging and pathology findings, exploring suitability for active surveillance, focal therapy, or alternative treatments.

    FAQs

    Q: How common is prostate cancer in the UK?
    A: Prostate cancer is the most commonly diagnosed cancer in the UK. Recent data indicates that over 64,000 new cases are recorded each year. Approximately 1 in 8 men will receive a diagnosis during their lifetime.
    Q: What is the lifetime risk of prostate cancer for men?
    A: The average lifetime risk is 1 in 8 for men in the UK. This risk increases to around 1 in 4 for Black men. Increasing age and a family history of the disease also significantly raise the likelihood of a diagnosis.
    Q: How many prostate cancer cases in the UK per year?
    A: Recent NHS figures show over 64,000 new diagnoses annually. Numbers have risen substantially in recent years, reflecting an ageing population and increased testing.
    Q: Is prostate cancer more common now?
    A: Yes, recorded diagnosis rates are higher than in previous decades. An ageing population, better detection methods like MRI imaging, and renewed public awareness have encouraged more men to seek testing, which explains some of this rise.
    Q: Where to get accurate prostate cancer stats?
    A: Accurate, current statistics are available through Cancer Research UK, Prostate Cancer UK, and national cancer registry reports from the NHS and the Office for National Statistics.

    References

    Cancer Research UK. (n.d.). Prostate cancer incidence statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence

    Cancer Research UK. (n.d.). Survival for all stages of prostate cancer. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/survival

    Prostate Cancer UK. (2026). Prostate cancer is now the most common cancer in the UK. Available at: https://prostatecanceruk.org/about-us/news-and-views/2026/01/prostate-most-common-cancer

    Prostate Cancer UK. (2026). Prostate cancer statistics. Available at: https://prostatecanceruk.org/for-health-professionals/data-and-evidence

    About UsBook Consultation